Targeted therapies in non‐small cell lung cancer and the potential role of AI interventions in cancer treatment

Tarunya Menon,Shubhang Gopal,Smita Rastogi Verma
DOI: https://doi.org/10.1002/bab.2356
2022-05-26
Biotechnology and Applied Biochemistry
Abstract:Non‐small cell lung cancer is the most prevalent lung cancer, and almost three‐fourths of patients are diagnosed in the advanced stage directly. In this stage, chemotherapy gives only a 15% five‐year survival rate. Since people have varied symptoms and reactions to a specific cancer type, treatment for that tumor is likely to fall short, complicating cancer therapy. Immunotherapy is a breakthrough treatment involving drugs targeting novel immune checkpoint inhibitors like CTLA‐4 and PD‐1/PD‐L1, along with combination therapies. In addition, the utility of engineered CAR‐T and CAR‐NK cells can be an effective strategy to promote the immune response against tumors. The concept of personalized cancer vaccines with the discovery of neoantigens loaded on dendritic cell vectors can also be an effective approach to cure cancer. Advances in genetic engineering tools like CRISPR/Cas9 mediated gene editing of T‐cells to enhance their effector function is another ray of hope. This review aims to provide an overview of recent developments in cancer immunotherapy, which can be used in first‐ and second‐line treatments in the clinical space. Further, the intervention of Artificial Intelligence to detect cancer tumors at an initial stage with the help of machine learning techniques is also explored. This article is protected by copyright. All rights reserved
biotechnology & applied microbiology,biochemistry & molecular biology
What problem does this paper attempt to address?